Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

DOES RLFTF HAVE GOOD REASON TO ACCELERATE???

By acquiring the rights to AdVita’s therapy formulation, Relief also will accelerate and secure RLF-100’s future development as an inhaled therapy for lung diseases, such as pulmonary sarcoidosis, that are associated with COVID-19. Other lung diseases associated with COVID-19, which also could potentially be treated by RLF-100, include checkpoint inhibitor-induced pneumonitis, and acute respiratory distress syndrome (ARDS).

https://sarcoidosisnews.com/2021/01/28/deal-gives-relief-therapeutics-intellectual-rights-potential-sarcoidosis-therapy-rlf-100/

This study is the first to show the immunoregulatory effect of VIP in humans, and supports the notion of inhaled VIP as an attractive future therapy to dampen exaggerated immune responses in lung disorders. Thus, the inhalation of neuropeptides may be developed into a new therapeutic principle for chronic inflammatory lung disorders in humans.

https://pubmed.ncbi.nlm.nih.gov/20442436/

There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation.

https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-45